Tango Therapeutics, Inc. - Common Stock (TNGX)

Tango Therapeutics (TNGX) reported Q2 2025 revenue below estimates but met EPS expectations, causing a 2.4% pre-market dip. Clinical progress in oncology trials remains a key focus.

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later this year.

TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.